A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Inclusion Criteria: * Adult male. * 18 to 59 years. * Androgenetic Alopecia (Hamilton-Norwood III-V). * Body mass index (BMI) ≥ 18.0 kg/m2, with a body weight ≥ 50 kg at screening. * Non-smoker. * Medically healthy without clinically significant abnormalities. * Willing and able to tolerate multiple injections and attend all study visits. * Willing to have blood drawn. Exclusion Criteria: * History or presence of significant pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically significant. * Uncontrolled diabetes mellitus. * Immunodeficiency disorders. * History of clinically significant heart disease. * History of risk factors for torsade de pointes. * Any dermatological disorders of the scalp. * History or clinical signs of keloids or hypertrophic scars. * History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen effluvium, or conditions other than AGA. * History of surgical correction of hair loss or hair transplant on the scalp. * History of radiation of the scalp at any time. * Use of semi-permanent hair products. * Use of an occlusive wig, hair extensions, or hair weaves for the duration of the study. * Use of cosmeceuticals or over-the-counter (OTC) hair regrowth products \< 2 weeks prior to the first dose of study drug. * Use of topical/local treatments. * Use of non-topical/…